Article
The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals.
Journal of the National Comprehensive Cancer Network : JNCCN - 1 Apr 2024
Zogopoulos George, Haimi Ido, Sanoba Shenin A, Everett Jessica N, Wang Yifan, Katona Bryson W, Farrell James J, Grossberg Aaron J, Paiella Salvatore, Klute Kelsey A, Bi Yan, Wallace Michael B, Kwon Richard S, Stoffel Elena M, Wadlow Raymond C, Sussman Daniel A, Merchant Nipun B, Permuth Jennifer B, Golan Talia, Raitses-Gurevich Maria, Lowy Andrew M, Liau Joy, Jeter Joanne M, Lindberg James M, Chung Daniel C, Earl Julie, Brentnall Teresa A, Schrader Kasmintan A, Kaul Vivek, Huang Chenchan, Chandarana Hersh, Smerdon Caroline, Graff John J, Kastrinos Fay, Kupfer Sonia S, Lucas Aimee L, Sears Rosalie C, Brand Randall E, Parmigiani Giovanni, Simeone Diane M
Abstract excerpt
BACKGROUND: Pancreatic adenocarcinoma (PC) is a highly lethal malignancy with a survival rate of only 12%. Surveillance is recommended for high-risk individuals (HRIs), but it is not widely adopted. To address this unmet clinical need and drive early diagnosis research, we established the Pancreatic Cancer Early Detection (PRECEDE) Consortium. METHODS: PRECEDE is a multi-institutional international collaboration...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.